Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer

Hear from global experts in this on-demand Webcast capturing a live CCO Webinar focused on leveraging PARP inhibitors and chemotherapy for optimal treatment of pancreatic cancer with BRCA1/2 and other DNA damage repair gene alterations.

Dirk Arnold, MD, PhD Michael J. Pishvaian, MD, PhD Released: October 8, 2020

Molecular Testing Considerations for Patients With Pancreatic Cancer

Treatment of Patients With BRCA Mutated Pancreatic Cancer: The Clinical Perspective

Download this slideset to review the latest data on molecular testing considerations for patients with pancreatic cancer.

Michael J. Pishvaian, MD, PhD Released: September 21, 2020

Download this slideset to review the latest data on treating patients with pancreatic cancer and BRCA mutations or other actionable alterations.

Dirk Arnold, MD, PhD Released: September 21, 2020

Now that olaparib is approved in the EU, how will your treatment of patients with pancreatic cancer change?

Dirk Arnold, MD, PhD Released: October 30, 2020